DelveInsight’s Severe Hypertriglyceridemia Market Insights report includes a comprehensive understanding of current treatment practices, Severe Hypertriglyceridemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

Severe Hypertriglyceridemia Overview

High amounts of triglycerides are a defining feature of the disease Hypertriglyceridemia. Triglyceride levels in patients with Severe Hypertriglyceridemia (SHTG) are more than three times normal. It causes a variety of dangerous conditions, including cardiovascular disease (CVD) and Acute Pancreatitis. High triglycerides may contribute to artery hardening or thickening (arteriosclerosis), which increases the risk of stroke, heart attack, and heart disease. Genetic problems, obesity, uncontrolled diabetes, and certain drugs can all contribute to the development of Severe Hypertriglyceridemia.

Primary and secondary hypertriglyceridemia are the two broad forms of severe hypertriglyceridemia. The former is caused by other underlying diseases and secondary circumstances, whereas the latter is caused by genetic problems. Primary hypertriglyceridemia has a molecular basis in less than 5% of cases, while secondary hypertriglyceridemia has no repeatable genetic susceptibility component.

Severe Hypertriglyceridemia symptoms are not noticeable, however, individuals with exceptionally high levels of triglycerides (more than 2,000 mg/dL) can develop persistent abdominal pain, nausea, vomiting, xanthomas (yellow-colored lumps on the skin), and severe pancreatitis.

Key Takeaways from the Severe Hypertriglyceridemia Market Report

• As per DelveInsight analysis, the Severe Hypertriglyceridemia market size in the 7MM was found to be approximately USD 3,060 million in 2021.
• As per the estimates, the total number of Hypertriglyceridemia prevalent cases associated in 7MM countries was approximately 154 million in 2021, out of which approximately 3 million cases were diagnosed prevalent cases of Severe Hypertriglyceridemia. 
• Leading Severe Hypertriglyceridemia companies Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., Afimmune Pharmaceutical, NorthSea Therapeutics B.V., Amryt Pharma, and others are working to develop a new medication for Severe Hypertriglyceridemia which can be available in the Severe Hypertriglyceridemia market in the upcoming years.
• The Severe Hypertriglyceridemia in the pipeline include Olezarsen, Pegozafermin (BIO89-100), ARO-APOC3, Epeleuton (DS102), NST-1024 (SEFA 1024), Lomitapide, and others.
• The expected launch of therapies and the increasing prevalence will lead to Severe Hypertriglyceridemia market growth during the forecast period. 

Discover more about therapies set to grab major Severe Hypertriglyceridemia market share @ Severe Hypertriglyceridemia Market Landscape

Severe Hypertriglyceridemia Epidemiology Segmentation

• As per DelveInsight, there were approx 3 million diagnosed Severe Hypertriglyceridemia prevalent cases in the 7MM in 2021.
• Among EU5 countries, Germany had the highest Severe Hypertriglyceridemia prevalence  in 2021.

The Severe Hypertriglyceridemia Market Report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

• Prevalent Cases of Hypertriglyceridemia 
• Diagnosed Prevalent Cases of Hypertriglyceridemia
• Severity-specific Diagnosed Prevalent Cases of Hypertriglyceridemia 
• Etiology-specific Diagnosed Prevalent Cases of Severe Hypertriglyceridemia   

Download the report to understand which factors are driving Severe Hypertriglyceridemia epidemiology trends @ Severe Hypertriglyceridemia Epidemiological Insights

Severe Hypertriglyceridemia Pipeline Therapies and Key Companies

• Olezarsen: Ionis Pharmaceuticals
• Pegozafermin (BIO89-100): 89bio, Inc.
• ARO-APOC3: Arrowhead Pharmaceuticals, Inc.
• Epeleuton (DS102): Afimmune Pharmaceutical
• NST-1024 (SEFA 1024): NorthSea Therapeutics B.V.
• Lomitapide: Amryt PharmaOthers

Scope of the Severe Hypertriglyceridemia Market Report

• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Severe Hypertriglyceridemia Companies: Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., Afimmune Pharmaceutical, NorthSea Therapeutics B.V., Amryt Pharma, and others
• Key Severe Hypertriglyceridemia Therapies: Olezarsen, Pegozafermin (BIO89-100), ARO-APOC3, Epeleuton (DS102), NST-1024 (SEFA 1024), Lomitapide, and others
• Severe Hypertriglyceridemia Therapeutic Assessment: Severe Hypertriglyceridemia current marketed and emerging therapies
• Severe Hypertriglyceridemia Market Dynamics: Severe Hypertriglyceridemia market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Severe Hypertriglyceridemia Unmet Needs, KOL’s views, Analyst’s views, Severe Hypertriglyceridemia Market Access and Reimbursement

Discover more about the future Severe Hypertriglyceridemia market share of treatment therapies @ Medication for Severe Hypertriglyceridemia Treatment

Table of Contents

Get in touch with our Business executive @ Pharama Consulting Services

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/